Neurobehavioral Research, Inc.

Cedarhurst, New York 11516

5 studies enrolling now · 59 studies all time

What they study most

Alcohol Use Disorder (AUD), Alzheimer's Disease, Bipolar Depression, Bipolar Disorder, Bipolar I Disorder, Bipolar II Disorder, Borderline Personality Disorder, Cognitive Impairment Associated With Schizophrenia, Depression, Depressive Disorder, Major, Fibromyalgia, Generalized Anxiety Disorder

Studies at this site

• Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — Recruiting now
• A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — Recruiting now
• A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia — Recruiting now
• A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) — Recruiting now
• A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity — Completed
• A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes — Running, not enrolling
• An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE) — Enrolling by invitation
• A Study to Test Different Doses of BI 1569912 in People With Depression — Completed
• Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population — Completed
• Zelquistinel in the Treatment of Major Depressive Disorder — Completed
• A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder — Stopped early
• A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study — Stopped early
• A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder — Completed
• Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients — Completed
• Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD) — Completed
• A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine — Completed
• Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder — Stopped early
• Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder — Completed
• Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression — Completed
• Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2) — Completed
• A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia — Completed
• A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia — Running, not enrolling
• A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder — Completed
• This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months — Stopped early
• Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions — Completed
• A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder — Completed
• A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder — Completed
• A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia — Completed
• A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) — Completed
• Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia — Stopped early
• Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia — Completed
• A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics — Completed
• Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD) — Completed
• Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD) — Stopped early
• Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder — Completed
• A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease — Completed
• A Twelve Week, Open Label Extension Study in Patients With Schizophrenia — Completed
• Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression — Completed
• Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients — Completed
• A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment. — Completed
• A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features — Stopped early
• POC Study in Partially Responsive Generalized Anxiety Disorder — Stopped early
• Lurasidone Low-Dose - High-Dose Study Study — Completed
• Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression — Completed
• Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects — Completed
• PEARL Schizophrenia Maintenance — Completed
• Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder — Completed
• Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder — Completed
• Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression — Stopped early
• Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression — Completed